Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Clinigen Group PLC    CLIN   GB00B89J2419

CLINIGEN GROUP PLC (CLIN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/22 05:53:25 am
753.67 GBp   +0.49%
2018CLINIGEN GROUP PLC : annual earnings release
2018CLINIGEN GROUP PLC : half-yearly sales release
2017CLINIGEN GROUP PLC : annual earnings release
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Clinigen : Accord Healthcare extend exclusive European clinical trial supply agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 03:51am EST

Clinigen Group plc (Clinigen), the global pharmaceutical and services company, announces that its Clinical Trial Service (CTS) business has extended its exclusive European clinical trial supply agreement with Accord Healthcare (Accord). Clinigen is also offering pharma companies an on demand service to Accords products, a first for the industry.

Clinigen and Accord have been partnered since 2012 to deliver oncology Injectable Products, including carboplatin, cisplatin and paclitaxel, into clinical trials. The extended agreement now covers Accords European Solid Dose Products, including those in the central nervous system, autoimmune, diabetes and anti-viral therapy areas.

The CTS team is the sole point of contact for all clinical trial supply enquiries, ensuring an effective and secure supply chain in the distribution of Accords European product portfolio to pharmaceutical manufacturers, contract research organizations (CROs), clinical trial contract packagers and other specialist service providers. The drugs are supplied for use as comparator, co-therapy, rescue and adjunctive drugs in clinical trials.

The on demand supply service will be available for any Clinigen client running clinical trials. They will be offered instant access to key products from Accord`s generic oncology Injectable Product portfolio. Products will be held in large batch sizes on consignment ready for instant dispatch to new and existing clinical trials.

This is the first type of dedicated service providing instant access to products solely for clinical trials in the industry and directly tackles the constant timeline and flexibility challenges experienced when running clinical trials.

Shaun Chilton, Group Chief Executive Officer of Clinigen, said:

This extended agreement builds on the strong partnership we have with Accord in providing access to its medicines for use in clinical trials.

The launch of our on demand offering demonstrates the ability we have across the Group and the specialisms we have in the supply and distribution of medicines. These capabilities enable us to provide the best possible service to those running clinical trials.

Phill Semmens, Senior Vice President Commercial, Accord Healthcare, EMENA, said:

We are delighted that the strong collaboration Accord and Clinigen have built over the past six years continues to expand with the agreement to include solid dose oral products.

The scope of this partnership is a first for the industry, allowing us to ensure that our products are available as comparators in a variety of vital clinical trials, helping to further medical knowledge and the identification of new treatment options to improve patient care.

(c) 2019 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CLINIGEN GROUP PLC
01/16CLINIGEN : Half year trading update
AQ
01/16CLINIGEN : Acquisitions spur Clinigen to profit and revenue growth
AQ
01/15CLINIGEN : establishes on-demand clinical trial supply chain
AQ
01/12CLINIGEN : Accord Healthcare extend exclusive European clinical trial supply agr..
AQ
01/11CLINIGEN : Extends exclusive european clinical trial sourcing and supply agreeme..
AQ
01/11CLINIGEN : extends European clinical trial agreement with Accord
AQ
2018CLINIGEN : Capital markets day
AQ
2018CLINIGEN : Capital Markets Day
PU
2018CLINIGEN : Completes acquisition of iqone healthcare
AQ
2018CLINIGEN : Annual report and accounts, and notice of agm
AQ
More news
Financials (GBP)
Sales 2019 455 M
EBIT 2019 95,0 M
Net income 2019 42,1 M
Debt 2019 163 M
Yield 2019 0,84%
P/E ratio 2019 23,27
P/E ratio 2020 16,73
EV / Sales 2019 2,56x
EV / Sales 2020 2,21x
Capitalization 1 001 M
Chart CLINIGEN GROUP PLC
Duration : Period :
Clinigen Group PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLINIGEN GROUP PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 12,7  GBP
Spread / Average Target 68%
EPS Revisions
Managers
NameTitle
Shaun Edward Chilton Chief Executive Officer & Executive Director
Peter Vance Allen Independent Non-Executive Chairman
Martin Abell Chief Financial Officer & Executive Director
Ivo Timmermans Chief Medical Officer
John Hartup Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CLINIGEN GROUP PLC-0.53%1 289
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS17.49%49 757
REGENERON PHARMACEUTICALS12.14%44 532
GENMAB-4.59%9 536
NEUROCRINE BIOSCIENCES, INC.28.18%8 300